Discrimination of COVID ‐19 From Inflammation‐Induced Cytokine Storm Syndromes Using Disease‐Related Blood Biomarkers
ConclusionSerum biomarker profiles clearly separate COVID-19 from MAS or secondary HLH in terms of distinguishing the severe systemic hyperinflammation that occurs following SARS –CoV-2 infection. These findings could be useful in determining the efficacy of drugs targeting key molecules and pathways specifically associated with systemic cytokine storm conditions in the treatment of COVID-19.
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Christoph Kessel,
Richard Vollenberg,
Katja Masjosthusmann,
Claas Hinze,
Helmut Wittkowski,
France Debaugnies,
Carole Nagant,
Francis Corazza,
Fr édéric Vély,
Gilles Kaplanski,
Charlotte Girard‐Guyonvarc’h,
Cem Gabay,
Hartmut Schmidt,
Tags: Brief Report Source Type: research